Teva Pharmaceutical Industries Ltd (TEVA)

51.20
0.43 0.83
NYSE : Health Care
Prev Close 51.63
Open 51.46
Day Low/High 51.11 / 52.29
52 Wk Low/High 48.01 / 66.55
Volume 10.62M
Avg Volume 5.53M
Exchange NYSE
Shares Outstanding 914.00M
Market Cap 48.62B
EPS 1.80
P/E Ratio 29.23
Div & Yield 1.36 (2.60%)

Latest News

Teva Confirms PTAB's Decisions On Two Patents In IPR Challenge To COPAXONE® 40 Mg

Teva Confirms PTAB's Decisions On Two Patents In IPR Challenge To COPAXONE® 40 Mg

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the '250 and '413 patents for 40 mg...

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

Teva Stock Drops After Patent Invalidated

Teva Stock Drops After Patent Invalidated

Teva was stock was trading sharply lower this afternoon after aspects of its patent for multiple sclerosis drug Copaxone were determined invalid.

A Backlash Materializes Against Soaring EpiPen Prices

A Backlash Materializes Against Soaring EpiPen Prices

Senators Grassley, Blumenthal and Klobuchar demand Mylan reduce the price of its dominant treatment for life-threatening allergies.

European Commission Grants Marketing Authorization For Teva's CINQAERO® (reslizumab)

European Commission Grants Marketing Authorization For Teva's CINQAERO® (reslizumab)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission has granted marketing authorization for CINQAERO ® (reslizumab) in the 28 countries of the European Union (EU) in...

Why Allergan is Fine Without Large M&A

Why Allergan is Fine Without Large M&A

The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.

Glaucoma Treatment Maker a $95M

Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan

The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.

Mylan's Time Leaning on EpiPens Is Rapidly Approaching an End

Mylan's Time Leaning on EpiPens Is Rapidly Approaching an End

The Pittsburgh-based pharmaceutical company has been steadily jacking up the price of the auto injectors since 2010 to bolster revenues.

Allergan Stock Is 'Misunderstood'

Allergan Stock Is 'Misunderstood'

AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.

These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now

These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

Jim Cramer -- Allergan Will Aggressively Buy Back Stock

Jim Cramer -- Allergan Will Aggressively Buy Back Stock

Allergan shares are down but management will take the opportunity to buy back its stock, Cramer says.

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.

Teva Announces Launch Of Generic Gleevec® Tablets In The United States

Teva Announces Launch Of Generic Gleevec® Tablets In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of the generic equivalent to Gleevec ®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multiple indications...

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

Why Allergan Can Head Higher Despite a Messy Quarter -- Plus Jim Cramer's Take

Why Allergan Can Head Higher Despite a Messy Quarter -- Plus Jim Cramer's Take

Allergan stock is down 19% year to date, but probably not for long. Over the next year, Allergan could trade much higher.

Will Teva Pharmaceuticals (TEVA) Stock Improve on Q2 Beat?

Will Teva Pharmaceuticals (TEVA) Stock Improve on Q2 Beat?

Teva Pharmaceuticals (TEVA) reported better-than-expected earnings and revenue before today's market open.

Teva Reports Second Quarter 2016 Results

Teva Reports Second Quarter 2016 Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2016.

Here Are Two Reasons to Buy Mylan Now

Here Are Two Reasons to Buy Mylan Now

The stock is breaking out of consolidation patterns on multiple timeframes.

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Deal rumors are deflating, but a takeover bid could reward holdouts.

Will Teva Pharmaceuticals (TEVA) Stock Be Lifted By Q2 Earnings?

Will Teva Pharmaceuticals (TEVA) Stock Be Lifted By Q2 Earnings?

Teva Pharmaceuticals (TEVA) is slated to report second-quarter earnings and revenue before tomorrow's market open.

Teva Announces Acquisition Of Anda Inc.

Teva Announces Acquisition Of Anda Inc.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that it has entered into a definitive agreement to purchase Allergan's Anda Inc.

(Graphic: Business Wire)

(Graphic: Business Wire)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan's generics business ("Actavis Generics").

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

These five technical setups are showing solid upside potential right now. Here's how to trade them from here.

We Will Get Some Whack in the Market This Week

And it will be enough to give some people concern.

Mylan's Weakness Shouldn't Last, So Buy Now

Mylan's Weakness Shouldn't Last, So Buy Now

An investor should make good money on any turn in the drug maker's business or in investor sentiment.

Teva Pharmaceuticals Initiates Voluntary Nationwide Recall Of Seven Lots Of Amikacin Sulfate Injection USP 500mg/2 ML (250 Mg/mL) And 1 Gram/4 ML (250 Mg/mL) Vials Due To Potential Of Glass Particulate Matter

Teva Pharmaceuticals Initiates Voluntary Nationwide Recall Of Seven Lots Of Amikacin Sulfate Injection USP 500mg/2 ML (250 Mg/mL) And 1 Gram/4 ML (250 Mg/mL) Vials Due To Potential Of Glass Particulate Matter

Teva Pharmaceuticals today announced a voluntary recall of seven lots of Amikacin Sulfate Injection USP, 500 mg/2mL (250 mg/mL) and 1 gram/4mL (250 mg/mL) vials due to the potential for the presence of glass particulate...

Allergan Cures Its Ailing Chart

Allergan Cures Its Ailing Chart

The stock has broken free of tiresome resistance in a big way.